课题基金 / 基金详情

Organic Anion Transporting Polypeptide (OATP), P-glycoprotein (P-gp), and Breast Cancer Resistance Protein (BCRP) transporters modulate tamoxifen response during breast cancer therapy

Organic Anion Transporting Polypeptide (OATP), P-glycoprotein (P-gp), and Breast Cancer Resistance Protein (BCRP) transporters modulate tamoxifen response during breast cancer therapy
有机阴离子转运多肽 (OATP)、P-糖蛋白 (P-gp) 和乳腺癌抗性蛋白 (BCRP) 转运蛋白在乳腺癌治疗期间调节他莫昔芬反应
批准号：
452037
负责人：
Kim Richard B
金额：
$47.93万
依托单位：
University of Western Ontario
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
未结题
起止时间：
2021-09-01 至 2026-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=452037&lang=en
关键词：
Drug Transporters Tamoxifen Therapy

项目摘要

项目成果

Kim Richard B的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Breast cancer was diagnosed in 26,900 Canadian women in 2019, accounting for 25% of all cancer diagnosis in women. Breast cancer patients with estrogen receptor positive cancers are usually treated, often for 5-10 years, with an antiestrogen medication ca
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integrated Precision Medicine Technology and Approach for Optimal Drug Therapy for Canadians
Clinical and pharmacogenomic predictors of inter-patient variation in direct acting oral anticoagulant (DOAC) plasma concentrations in real-world patients
  • 批准号：
    338124
  • 项目类别：
    Miscellaneous Programs
  • 资助金额：
    $36.24万
  • 财政年份：
    2015
  • 负责人：
    Kim Richard B
  • 依托单位：
    University of Western Ontario
Best Brains Exchange: ''Canada as a Leader in the Development and Deployment of Precision/Personalized Medicine'' March 23, 2015 in Ottawa, ON.
DSEN Pharmacogenomics of Adverse Reaction Events National Team (DSEN-PREVENT)
海外基金